Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript

Sergio Traversa: Well, thank you, and in summary, we remain confident that, we do have an approvable drug in REL-1017, and are excited by the potential of our novel psilocybin, and derivative program. So, we look forward, to reporting on progress, with our pipeline – in the months ahead. And to close, I’m grateful to the Relmada team, for their continued hard work and dedication to executing on our mission. And I would also like to extend my sincere thanks, to the patients and clinical partners involved in the REL-1017 trials, for their participation in the advancement, of this promising investigational medicine, through development. Thank you very much to everyone.

Operator: Thank you. That concludes our conference today. Thank you for participating. You may all disconnect.